NCT05726838 - The Belgian REAL (BE.REAL) Registry | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Atherosclerotic Cardiovascular Disease

Interventions

OTHER

Inclisiran

There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.

Trial Locations (15)

1020

RECRUITING

Novartis Investigative Site, Brussels

1070

RECRUITING

Novartis Investigative Site, Anderlecht

2300

RECRUITING

Novartis Investigative Site, Turnhout

2650

RECRUITING

Novartis Investigative Site, Edegem

2800

RECRUITING

Novartis Investigative Site, Mechelen

2930

RECRUITING

Novartis Investigative Site, Brasschaat

3000

RECRUITING

Novartis Investigative Site, Leuven

3600

RECRUITING

Novartis Investigative Site, Genk

4000

RECRUITING

Novartis Investigative Site, Liège

4500

RECRUITING

Novartis Investigative Site, Huy

5530

RECRUITING

Novartis Investigative Site, Yvoir

7100

RECRUITING

Novartis Investigative Site, Haine-Saint-Paul

8500

RECRUITING

Novartis Investigative Site, Kortrijk

9000

RECRUITING

Novartis Investigative Site, Ghent

9300

RECRUITING

Novartis Investigative Site, Aalst